Oxaliplatin (L-OHP) is a third-generation platinum (Pt) analogue where the Pt atom is linked to a diaminocyclohexane structure joined to oxalic acid. It has been found to be active as a single agent in advanced colorectal cancer [1] , to synergise with 5-fluorouracil (5-FU) and folinic acid (FA) [2] , and to have a cumulative sensitive neuropathy as the dose-limiting toxicity. Allergic reactions to L-OHP have been described in the literature, including skin rashes and itching, redness of the face, dizziness, shortness of breath and anxiety [3, 4] . The incidence rate of this important side-effect in clinical practice is reported to be between ∼2% and up to 12% [5] . As with carboplatin and cisplatin, allergic reaction happens after many courses of therapy, indicating that prolonged exposure to this agent has a role in the patient becoming sensitized. Another factor that limits this incidence rate is that patients do not usually receive more than 10-12 courses of L-OHP, due to drug interruption for progression of disease or for neurotoxicity.
In a recent paper, Zanotti et al. [6] described the use of a skintesting protocol for carboplatin hypersensitivity reactions (HR). In order to screen patients for risk of HR they used a standardized skin test: injecting 0.02 ml aliquots of a carboplatin preparation s.c. into patients undergoing chemotherapy with carboplatin. The study confirmed the predictive value of the positive and negative results of this skin test to identify patients at risk of carboplatin HR.
We have studied 20 patients with advanced colorectal cancer treated with a 5-FU, FA and L-OHP combination. Patient data are shown in Table 1 . We applied the skin testing to five patients who had symptoms that were consistent with the diagnosis of L-OHP HR to confirm the allergic basis of their clinical profiles. As a control group, the same test was applied to 15 patients with no history of previous HR to L-OHP. In order to verify the allergic nature of these reactions, prick tests and intradermal tests were performed. Prick tests were performed in both groups of patients with a drop of a solution containing L-OHP diluted to 3 mg/ml in 5% glucose (which is the concentration we currently use to deliver this drug). Intradermal tests with 0.1 ml of the same solution were injected s.c. on the planar surface of the arm. Prick tests and intradermal tests were also performed with solutions of cisplatin, carboplatin, and of two Pt salts (hexachloroplatinic acid and potassium tetrachloroplatinate) that are known to cause allergic reactions in occupational workers [7] .
In the five patients with clinical manifestations due to L-OHP HR, prick tests gave negative results. Intradermal tests with L-OHP elicited an immediate positive reaction in four out of five patients. Prick tests and intradermal tests performed with solutions of cisplatin, carboplatin, and the two Pt salts all gave negative results.
In the patient with a negative intradermal skin test, L-OHP rechallenge was attempted, but it resulted in a severe HR, which required the patient's admission to hospital. A subsequent prick test was performed, which now became positive. In all five patients, L-OHP was stopped and the patients continued therapy with 5-FU and FA without any further problems ( Table 2 ). The same tests were carried out in 15 other subjects undergoing therapy with 5-FU-FA-L-OHP without any skin reactions: no false-positive test was found.
Through this experience, we have shown that an intradermal skin test with L-OHP confirmed the clinical diagnosis of L-OHP HR in four out of five patients, 80%. The test was negative in all the 15 patients with no previous history of L-OHP HR. The characteristics of the clinical manifestations suggest a type 1 HR, i.e. IgE mediated. The mechanisms by which L-OHP can cause HR need to be established. We did not test for specific anti-Pt antibodies, 1,2-diaminocyclohexane or oxalic acid. The lack of HR to other Pt salts seems to indicate that the whole molecule of L-OHP, rather than just the Pt, plays a pivotal role in eliciting immediate HR. We have previously demonstrated that an immunological response is the basis of haemolytic anaemia caused by L-OHP [8] , and it may be speculated that the binding of L-OHP to cutaneous receptors alters or modifies some ligands and promotes an immunological response. These data partly confirm the findings described by Meyer et al. [5] . They report a cross-reactivity with carboplatin, which was not the case in our series. Moreover, they stated that L-OHP reintroduction did not lead to any severe reaction, whereas, in our only patient with a false negative test, the subsequent dose of L-OHP necessitated the patient's admission to hospital.
We can conclude that for patients with a suspected L-OHP HR an intradermal skin test with L-OHP can be performed in order to confirm the allergic basis of reported symptoms. The exact mechanism underlying HR needs to be clarified in order to prevent or decrease the extent of HR and to allow continuation of this important drug. The predictive use of this test in patients with a cumulative L-OHP dose >600 mg/m 2 could be tested in a prospective study in order to identify patients at risk of HR. 
